Bal Pharma Ltd
NSE: BALPHARMA BSE: 524824
₹64.87
(7.37%)
Thu, 02 Apr 2026, 05:43 pm
Market Cap957.48M
PE Ratio10.96
Dividend1.82
Health Technology
Pharmaceuticals: Major
24.5KBal Pharma Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Bal Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- The company is paying a dividend however it is incurring a loss.
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Bal Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Bal Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Bal Pharma has been profitable on average in the past, therefore cash runway is not a concern.
- Bal Pharma has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 1.5x debt.
- Bal Pharma's cash and other short term assets cover its long term commitments.
- Debt is not well covered by operating cash flow (6.8%, less than 20% of total debt).
- The level of debt compared to net worth has increased over the past 5 years (85.7% vs 205.1% today).
- Bal Pharma is making a loss, therefore interest payments are not well covered by earnings.
- Bal Pharma's level of debt (205.1%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Bal Pharma board of directors is less than 3 years, this suggests a new board.
- Shailesh's remuneration is higher than average for companies of similar size in India.
- Shailesh's compensation has increased whilst company is loss making.
- The average tenure for the Bal Pharma management team is less than 2 years, this suggests a new team.
misc
- Bal Pharma is not covered by any analysts.
- Bal Pharma has significant price volatility in the past 3 months.
past
- Unable to compare Bal Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Bal Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Bal Pharma used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- It is difficult to establish if Bal Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Bal Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Bal Pharma's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Bal Pharma is good value based on assets compared to the IN Pharmaceuticals industry average.
- BSE:524824 is up 14% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524824 is up 14% outperforming the market in India which returned 8% over the past month.
- Bal Pharma's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Bal Pharma's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Bal Pharma is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Bal Pharma is loss making, we can't compare the value of its earnings to the India market.
- 524824 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524824 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800